Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Shares of Novo Nordisk (NYSE:NVO) rose 1% following news that the company has submitted an application to the European Medicines Agency (EMA) to approve a higher dose of its obesity treatment, Wegovy.

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Investing.com -- Novo Nordisk (NYSE: NVO) stock rose 1% after the company announced it has submitted an application to the ...

As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. | As summer began and ...

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

STORY: Novo Nordisk is to collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy.Under the deal to ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Novo Nordisk NOVO.B 3.06 % increase; green up pointing triangle plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm ...